Shares of Surmodics SRDX were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 148.65% over the past year to ($0.18), which missed the estimate of ($0.08).
Revenue of $22,543,000 declined by 26.85% from the same period last year, which beat the estimate of $20,770,000.
Guidance
Surmodics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Nov 04, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/72noqvys
Recent Stock Performance
Company's 52-week high was at $49.00
52-week low: $22.06
Price action over last quarter: down 18.88%
Company Profile
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using our technology to provide solutions to a difficult medical device and diagnostic challenges. It has two reportable segments: Medical device unit and Vitro diagnostics unit. Surmodics derives most of its revenue from the Medical device segment.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.